Oncternal Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Oncternal Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
2.4%
Buyback Yield
| Total Shareholder Yield | 2.4% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation
Jun 14
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?
Mar 03Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Nov 06Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely
Jul 12We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Jan 12FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy
Oct 03Oncternal Therapeutics begins phase 3 study of zilovertamab
Sep 27Oncternal Therapeutics: Selling For Under Cash Value
Sep 02Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M
Aug 09Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Aug 07Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study
Jul 14Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve
Jun 07We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Apr 12Oncternal Therapeutics: Trading Near Cash With Impressive Results
Jan 04Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans
Nov 09Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company
Oct 10Oncternal: Solid Data In 2 Cancers With High Unmet Need
Jun 17We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth
May 05Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ONCT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ONCT's dividend payments have been increasing.
Dividend Yield vs Market
| Oncternal Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ONCT) | n/a |
| Market Bottom 25% (US) | 1.3% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (ONCT) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate ONCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ONCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ONCT's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ONCT has not reported any payouts.